Two mild, self-limited adverse events occurred: upper respiratory tract infection in one and transient alanine aminotransferase elevation in the other.<h4>Discussion</h4>This is the first report of efgartigimod use in pediatric patients with CIDP. The gene discussed is GPT; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.